Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
The integration and transition of the brands are expected to be completed by June 2022.
Subscribe To Our Newsletter & Stay Updated
